Literature DB >> 21207249

German national case collection for familial pancreatic cancer (FaPaCa): ten years experience.

Ralph Schneider1, Emily P Slater, Mercede Sina, Nils Habbe, Volker Fendrich, Elvira Matthäi, Peter Langer, Detlef K Bartsch.   

Abstract

Familial pancreatic cancer (FPC) is a rare hereditary tumor syndrome. The 10-years experience of the national case collection for familial pancreatic cancer of Germany (FaPaCa) is reported. Since 1999 FaPaCa has collected families with at least two first-degree relatives with confirmed pancreatic cancer (PC), who did not fulfill the criteria of other hereditary tumor syndromes. Histopathological verification of tumor diagnoses, and genetic counseling were prerequisites for enrollment of families in FaPaCa. 94 of 452 evaluated families fulfilled the criteria for partaking in FaPaCa. PC represented the sole tumor entity in 38 (40%) families. In 56 families additional tumor types occurred, including breast cancer (n = 28), colon cancer (n = 20) and lung cancer (n = 11). In 70 (74%) families the pattern of inheritance was consistent with an autosomal dominant trait. Compared to the preceding generation, a younger age of onset was observed in the offspring of PC patients (median: 57 vs. 69 years), indicating anticipation. Mutation analyses of BRCA2, PALB2, CDKN2a, RNASEL, STK11, NOD2, CHEK2 and PALLD, revealed deleterious causative germline mutations of BRCA2 and PALB2 in 2 of 70 (3%) and 2 of 41 (4.9%) German FPC families, respectively. Prospective PC screening with EUS, MRI and MRCP detected precancerous lesions (IPMN, multifocal PanIN2/3) or carcinoma in 5.5% (4 of 72) to 12.5% (9 of 72) of individuals at risk, depending on histological verification. Appropriate inclusion of families at high risk for PC in registries, such as FaPaCa, provides a unique and excellent tool to gain clinical and genetic knowledge of FPC. Focused research projects can be conducted most efficiently, when data of different FPC registries are combined.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21207249     DOI: 10.1007/s10689-010-9414-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  38 in total

1.  Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases.

Authors:  S E Applebaum; J A Kant; D C Whitcomb; I H Ellis
Journal:  Med Clin North Am       Date:  2000-05       Impact factor: 5.456

2.  Familial pancreatic cancer (Part 1): Genetic pathology review.

Authors:  H T Lynch; S J Lanspa; R J Fitzgibbons; T Smyrk; M L Fitzsimmons; J McClellan
Journal:  Nebr Med J       Date:  1989-05

Review 3.  Management strategies for patients with hereditary pancreatic cancer.

Authors:  Teresa A Brentnall
Journal:  Curr Treat Options Oncol       Date:  2005-09

Review 4.  Hereditary pancreatic cancer.

Authors:  H T Lynch; R E Brand; C A Deters; T G Shaw; J F Lynch
Journal:  Pancreatology       Date:  2001       Impact factor: 3.996

5.  No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma.

Authors:  Robert Grützmann; Christopher McFaul; Detlef K Bartsch; Mercedes Sina-Frey; Harald Rieder; Rainer Koch; Emma McCarthy; William Greenhalf; John P Neoptolemos; Hans Detlev Saeger; Christian Pilarsky
Journal:  Cancer Lett       Date:  2004-10-08       Impact factor: 8.679

6.  The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.

Authors:  J W Poley; I Kluijt; D J Gouma; F Harinck; A Wagner; C Aalfs; C H J van Eijck; A Cats; E J Kuipers; Y Nio; P Fockens; M J Bruno
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

7.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

Authors:  Kathleen M Murphy; Kieran A Brune; Constance Griffin; Jennifer E Sollenberger; Gloria M Petersen; Ravi Bansal; Ralph H Hruban; Scott E Kern
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

8.  Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer.

Authors:  P Langer; P H Kann; V Fendrich; N Habbe; M Schneider; M Sina; E P Slater; J T Heverhagen; T M Gress; M Rothmund; D K Bartsch
Journal:  Gut       Date:  2009-05-25       Impact factor: 23.059

9.  BRCA2 germline mutations in familial pancreatic carcinoma.

Authors:  Stephan A Hahn; Bill Greenhalf; Ian Ellis; Mercedes Sina-Frey; Harald Rieder; Birgit Korte; Berthold Gerdes; Ralf Kress; Andreas Ziegler; John A Raeburn; Donata Campra; Robert Grützmann; Helga Rehder; Matthias Rothmund; Wolff Schmiegel; John P Neoptolemos; Detlef K Bartsch
Journal:  J Natl Cancer Inst       Date:  2003-02-05       Impact factor: 13.506

10.  Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families.

Authors:  D K Bartsch; P Langer; N Habbe; E Matthäi; B Chaloupka; M Sina; S A Hahn; E P Slater
Journal:  Clin Genet       Date:  2009-12-22       Impact factor: 4.438

View more
  59 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

2.  Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model.

Authors:  Pari V Pandharipande; Curtis Heberle; Emily C Dowling; Chung Yin Kong; Angela Tramontano; Katherine E Perzan; William Brugge; Chin Hur
Journal:  Radiology       Date:  2014-11-12       Impact factor: 11.105

Review 3.  Genetic predisposition to pancreatic cancer.

Authors:  Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 4.  Familial pancreatic cancer--status quo.

Authors:  Volker Fendrich; Peter Langer; Detlef K Bartsch
Journal:  Int J Colorectal Dis       Date:  2013-08-16       Impact factor: 2.571

Review 5.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

Review 6.  Early detection of pancreatic cancer.

Authors:  Stephen P Pereira; Lucy Oldfield; Alexander Ney; Phil A Hart; Margaret G Keane; Stephen J Pandol; Debiao Li; William Greenhalf; Christie Y Jeon; Eugene J Koay; Christopher V Almario; Christopher Halloran; Anne Marie Lennon; Eithne Costello
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-02

7.  High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.

Authors:  Aimee L Lucas; Reena Shakya; Marla D Lipsyc; Elana B Mitchel; Sheila Kumar; Caroline Hwang; Liyong Deng; Catherine Devoe; John A Chabot; Matthias Szabolcs; Thomas Ludwig; Wendy K Chung; Harold Frucht
Journal:  Clin Cancer Res       Date:  2013-05-08       Impact factor: 12.531

Review 8.  [Familial pancreatic carcinoma].

Authors:  F Ehehalt; R Grützmann
Journal:  Chirurg       Date:  2011-08       Impact factor: 0.955

Review 9.  Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC).

Authors:  Mei Hua Wong; Chuen Seng Tan; Soo Chin Lee; Yvonne Yong; Aik Seng Ooi; Joanne Ngeow; Min Han Tan
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

Review 10.  Identifying people at a high risk of developing pancreatic cancer.

Authors:  Alison P Klein
Journal:  Nat Rev Cancer       Date:  2012-12-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.